UNSPSC 51292011: Fluoxetine

This classification denotes a selective serotonin reuptake inhibitor and antidepressant agent with the molecular formula C17H18F3NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 01K63SUP8D, chemically known as (+) or (-)-n-methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine but generally known as fluoxetine, which bears US NIH Compound Identifier 3386. European Medicines Agency schedules Fluoxetine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07723MIG.

UNSPSC 51292011 Fluoxetine is a Commodity code that covers pharmaceutical products for state and local procurement, though recent activity shows the code is being applied to broader pharmaceutical and drug-management solicitations beyond fluoxetine specifically. State and local governments buying under this code procure generic pharmaceuticals, over-the-counter products, and related drug-management systems through competitive bidding processes. Issuing bodies include state health and human services agencies, county health departments, and cooperative purchasing alliances serving multiple jurisdictions. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is a standout repeat buyer, establishing multi-award contracts for generic pharmaceuticals distributed to participating state and local facilities across multiple states. Work ranges from supplying manufactured pharmaceuticals with specific National Drug Codes and packaging configurations to procuring drug deactivation and harm-reduction systems like naloxone kits for community health delivery.

Recent activity spans Florida, Minnesota, Oregon, and Texas. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information on direct contracting between state pharmacy programs and pharmaceutical manufacturers outside traditional pharmacy benefit manager and group purchasing organization channels. MMCAP issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026, requiring vendors to supply products through three authorized wholesalers with contract effectiveness July 1, 2026, and evaluation weighted 75 percent on price competitiveness, 10 percent on fixed pricing, and the remainder on administrative compliance, EDI capability, and fee structures.